Elicio Therapeutics, Inc. (ELTX)
NASDAQ · Manufacturing · Pharmaceutical preparations
ELTX price, last 12 months
Key stats
- Previous close
- $1.59
- Open
- $1.61
- Day range
- $1.42 – $1.61
- 52-week range
- $1.25 – $16.00
- Volume
- 131.6K
- Avg volume (20 days)
- 330.8K
- Market cap
- $42.5M
Performance
Technicals and fundamentals
About Elicio Therapeutics, Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $42.5M